Main description:

With a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book builds upon topics discussed in the first edition (2012) where recent innovations warrant elaboration. This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students.

Contents:

1. Introduction.- 2. Translational Considerations and Challenges: An Overview.- 3. Considerations for Construct and Affinity Design Goals.- 4. Epitope Characterization and Isotype Selection.- 5. Biophysical Considerations for Development of Antibody-Based Therapeutics.- 6. Novel Technologies for Generation of Bispecific Constructs.- 7. Stimulus-Response Mechanisms: An Overview.- 8. Evaluation of Tumor Growth Inhibition in Preclinical Tumor Models -A Quantitative Approach.- 9. Application of Proof-of-Mechanism Biomarkers (POM) in Design and Development of Biologics Modalities.- 10. Antibody Drug Conjugates: Translational Considerations.- 11. Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs.- 12. Translational Biomarkers: Application in the Clinical Development of Combination Therapies.